The Association of Inflammatory Related Markers with the Prognosis in Elderly Patients with Colorectal Cancer

References

• Siegel RL, Wagle NS, Cercek A, Smith RA, Jemal A. Colorectal cancer statistics, 2023. CA Cancer J Clin. 2023;73(3):233–254. doi:10.3322/caac.21772
   PubMed Web of Science ®Google Scholar
• Howladern NA, Krapcho M, Miller D, et al. SEER cancer statistics review; 1975–2018.
   Google Scholar
• Sanoff HK, Goldberg RM. Colorectal cancer treatment in older patients. Gastrointest Cancer Res. 2007;1(6):248–253.
   PubMedGoogle Scholar
• Osseis M, Nehmeh WA, Rassy N, et al. Surgery for T4 colorectal cancer in older patients: determinants of outcomes. J Pers Med. 2022;12(9):1534. doi:10.3390/jpm12091534
   PubMed Web of Science ®Google Scholar
• Brenner H, Kloor M, Pox CP. Colorectal cancer. Lancet. 2014;383(9927):1490–1502. doi:10.1016/S0140-6736(13)61649-9
   PubMed Web of Science ®Google Scholar
• Fan XJ, Wan XB, Fu XH, et al. Phosphorylated p38, a negative prognostic biomarker, complements TNM staging prognostication in colorectal cancer. Tumour Biol. 2014;35(10):10487–10495. doi:10.1007/s13277-014-2320-3
   PubMedGoogle Scholar
• Boussios S, Ozturk MA, Moschetta M, et al. The developing story of predictive biomarkers in colorectal cancer. J Pers Med. 2019;9(1):12. doi:10.3390/jpm9010012
   PubMed Web of Science ®Google Scholar
• Balkwill F, Mantovani A. Inflammation and cancer: back to Virchow? Lancet. 2001;357(9255):539–545. doi:10.1016/S0140-6736(00)04046-0
   PubMed Web of Science ®Google Scholar
• Punt S, Dronkers EA, Welters MJ, et al. A beneficial tumor microenvironment in oropharyngeal squamous cell carcinoma is characterized by a high T cell and low IL-17(+) cell frequency. Cancer Immunol Immunother. 2016;65(4):393–403. doi:10.1007/s00262-016-1805-x
   PubMed Web of Science ®Google Scholar
• Shalapour S, Karin M. Immunity, inflammation, and cancer: an eternal fight between good and evil. J Clin Invest. 2015;125(9):3347–3355. doi:10.1172/JCI80007
   PubMed Web of Science ®Google Scholar
• West NR, McCuaig S, Franchini F, Powrie F. Emerging cytokine networks in colorectal cancer. Nat Rev Immunol. 2015;15(10):615–629. doi:10.1038/nri3896
   PubMed Web of Science ®Google Scholar
• Chen JH, Zhai ET, Yuan YJ, et al. Systemic immune-inflammation index for predicting prognosis of colorectal cancer. World J Gastroenterol. 2017;23(34):6261–6272. doi:10.3748/wjg.v23.i34.6261
   PubMed Web of Science ®Google Scholar
• Nozoe T, Matono R, Ijichi H, Ohga T, Ezaki T. Glasgow Prognostic Score (GPS) can be a useful indicator to determine prognosis of patients with colorectal carcinoma. Int Surg. 2014;99(5):512–517. doi:10.9738/INTSURG-D-13-00118.1
   PubMed Web of Science ®Google Scholar
• Li Y, Jia H, Yu W, et al. Nomograms for predicting prognostic value of inflammatory biomarkers in colorectal cancer patients after radical resection. Int J Cancer. 2016;139(1):220–231. doi:10.1002/ijc.30071
   PubMed Web of Science ®Google Scholar
• Zou ZY, Liu HL, Ning N, et al. Clinical significance of pre-operative neutrophil lymphocyte ratio and platelet lymphocyte ratio as prognostic factors for patients with colorectal cancer. Oncol Lett. 2016;11(3):2241–2248. doi:10.3892/ol.2016.4216
   PubMed Web of Science ®Google Scholar
• Nakamura Y, Shida D, Boku N, et al. Lymphocyte-to-C-reactive protein ratio is the most sensitive inflammation-based prognostic score in patients with unresectable metastatic colorectal cancer. Dis Colon Rectum. 2021;64(11):1331–1341. doi:10.1097/DCR.0000000000002059
   PubMed Web of Science ®Google Scholar
• Liang Y, Xiao W, Guan YX, et al. Prognostic value of the C-reactive protein/Albumin Ratio (CAR) in patients with operable soft tissue sarcoma. Oncotarget. 2017;8(58):98135–98147. doi:10.18632/oncotarget.20990
   PubMedGoogle Scholar
• Zhang HY, Xie HL, Ruan GT, et al. Lymphocyte to C-reactive protein ratio could better predict the prognosis of patients with stage IV cancer. BMC Cancer. 2022;22(1):1080. doi:10.1186/s12885-022-10145-x
   PubMed Web of Science ®Google Scholar
• Kurosaki T, Kawakami H, Mitani S, et al. Glasgow Prognostic Score (GPS) and tumor response as biomarkers of nivolumab monotherapy in third- or later-line setting for advanced gastric cancer. In Vivo. 2020;34(4):1921–1929. doi:10.21873/invivo.11989
   PubMed Web of Science ®Google Scholar
• Chiu JL. Analysis of older adults under home care in Taiwan’s ageing society. Comput Intell Neurosci. 2022;2022(8687947). doi:10.1155/2022/8687947
   PubMedGoogle Scholar
• Ishizuka M, Nagata H, Takagi K, Horie T, Kubota K. Inflammation-based prognostic score is a novel predictor of postoperative outcome in patients with colorectal cancer. Ann Surg. 2007;246(6):1047–1051. doi:10.1097/SLA.0b013e3181454171
   PubMed Web of Science ®Google Scholar
• Nozoe T, Iguchi T, Egashira A, et al. Significance of modified Glasgow prognostic score as a useful indicator for prognosis of patients with gastric carcinoma. Am J Surg. 2011;201(2):186–191. doi:10.1016/j.amjsurg.2010.01.030
   PubMed Web of Science ®Google Scholar
• Proctor MJ, Morrison DS, Talwar D, et al. An inflammation-based prognostic score (mGPS) predicts cancer survival independent of tumour site: a Glasgow inflammation outcome study. Br J Cancer. 2011;104(4):726–734. doi:10.1038/sj.bjc.6606087
   PubMed Web of Science ®Google Scholar
• Inamoto S, Kawada K, Okamura R, Hida K, Sakai Y. Prognostic impact of the combination of neutrophil-to-lymphocyte ratio and Glasgow prognostic score in colorectal cancer: a retrospective cohort study. Int J Colorectal Dis. 2019;34(7):1303–1315. doi:10.1007/s00384-019-03316-z
   PubMed Web of Science ®Google Scholar
• Yamamoto T, Kawada K, Obama K. Inflammation-related biomarkers for the prediction of prognosis in colorectal cancer patients. Int J Mol Sci. 2021;22(15):8002. doi:10.3390/ijms22158002
   PubMed Web of Science ®Google Scholar
• Lee SC, Huh JW, Lee WY, et al. Prognostic value of serum inflammatory markers in colorectal cancer. Int J Colorectal Dis. 2020;35(7):1211–1219. doi:10.1007/s00384-020-03591-1
   PubMed Web of Science ®Google Scholar
• Zhang CX, Wang SY, Chen SQ, et al. Association between pretreatment Glasgow prognostic score and gastric cancer survival and clinicopathological features: a meta-analysis. Onco Targets Ther. 2016;9:3883–3891. doi:10.2147/OTT.S103996
   PubMed Web of Science ®Google Scholar
• Wang DS, Ren C, Qiu MZ, et al. Comparison of the prognostic value of various preoperative inflammation-based factors in patients with stage III gastric cancer. Tumour Biol. 2012;33(3):749–756. doi:10.1007/s13277-011-0285-z
   PubMedGoogle Scholar
• Zhou QP, Li XJ. C-reactive protein to albumin ratio in colorectal cancer: a meta-analysis of prognostic value. Dose Response. 2019;17(4):1559325819889814. doi:10.1177/1559325819889814
   Web of Science ®Google Scholar
• Liu Y, Chen S, Zheng C, et al. The prognostic value of the preoperative c-reactive protein/albumin ratio in ovarian cancer. BMC Cancer. 2017;17(1):285. doi:10.1186/s12885-017-3220-x
   PubMed Web of Science ®Google Scholar
• Adeleke S, Haslam A, Choy A, et al. Microsatellite instability testing in colorectal patients with Lynch syndrome: lessons learned from a case report and how to avoid such pitfalls. Per Med. 2022;19(4):277–286. doi:10.2217/pme-2021-0128
   PubMedGoogle Scholar
• Ying HQ, Deng QW, He BS, et al. The prognostic value of preoperative NLR, d-NLR, PLR and LMR for predicting clinical outcome in surgical colorectal cancer patients. Med Oncol. 2014;31(12):305. doi:10.1007/s12032-014-0305-0
   PubMed Web of Science ®Google Scholar
• Pine JK, Morris E, Hutchins GG, et al. Systemic neutrophil-to-lymphocyte ratio in colorectal cancer: the relationship to patient survival, tumour biology and local lymphocytic response to tumour. Br J Cancer. 2015;113(2):204–211. doi:10.1038/bjc.2015.87
   PubMed Web of Science ®Google Scholar